New drug cocktail targets Hard-to-Treat tumors
NCT ID NCT05417594
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug can shrink or slow tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD9574 (an experimental drug taken by mouth, sometimes combined with other anti-cancer drugs)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1/2a) trial with only 695 participants, so the drug may not prove effective or safe enough to move forward. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNLa Jolla, California, 92093, United States
-
Research Site
RECRUITINGLos Angeles, California, 90095, United States
-
Research Site
RECRUITINGSan Francisco, California, 94143, United States
-
Research Site
RECRUITINGChicago, Illinois, 60611, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGNew York, New York, 10040, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
COMPLETEDPortland, Oregon, 97239, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
WITHDRAWNRichmond, Virginia, 23298, United States
-
Research Site
RECRUITINGDarlinghurst, 2010, Australia
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGRandwick, 2031, Australia
-
Research Site
WITHDRAWNBayern, 80337, Germany
-
Research Site
WITHDRAWNBerlin, 13353, Germany
-
Research Site
WITHDRAWNHeidelberg, 69120, Germany
-
Research Site
WITHDRAWNMainz, 55131, Germany
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 03722, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGA Coruña, 15006, Spain
-
Research Site
RECRUITINGBarcelona, 8035, Spain
-
Research Site
RECRUITINGMálaga, 29010, Spain
-
Research Site
RECRUITINGPozuelo de Alarcón, 28223, Spain
-
Research Site
RECRUITINGSant Cugat del Vallès, 08195, Spain
-
Research Site
RECRUITINGSeville, 41013, Spain
-
Research Site
RECRUITINGLund, 22185, Sweden
-
Research Site
RECRUITINGStockholm, 118 83, Sweden
-
Research Site
RECRUITINGGlasgow, Scotland, G12 0YN, United Kingdom
-
Research Site
RECRUITINGLondon, EC1M 6BQ, United Kingdom
-
Research Site
RECRUITINGNewcastle upon Tyne, NE7 7DN, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- New drug cocktail aims to shrink recurrent ovarian tumors